Sign Up to like & get
recommendations!
1
Published in 2020 at "Progress in Neuro-Psychopharmacology and Biological Psychiatry"
DOI: 10.1016/j.pnpbp.2019.109832
Abstract: Pharmacological interventions that selectively activate serotonin 5-hydroxytryptramine-1A (5-HT1A) heteroreceptors may prevent or attenuate the consequences of brain ischemic episodes. The present study investigated whether the preferential 5-HT1A postsynaptic receptor agonist NLX-101 (a.k.a. F15599) mitigates cognitive…
read more here.
Keywords:
brain ischemia;
neuroplasticity mice;
brain;
ht1a postsynaptic ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Journal of Psychopharmacology"
DOI: 10.1177/0269881119860666
Abstract: Background: NLX-101 (also known as F15599) is a highly selective and efficacious ‘biased’ agonist at cortical 5-hydroxytryptamine 1A (5-HT1A) heteroreceptors. In rodents, it possesses marked antidepressant-like activity, potently and completely abolishing immobility in the forced…
read more here.
Keywords:
biased agonist;
cortical hydroxytryptamine;
model;
rat chronic ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Pharmaceuticals"
DOI: 10.3390/ph15030337
Abstract: Depression is the most prevalent of the mental illnesses and serotonin (5-hydroxytryptamine, 5-HT) is considered to be the major neurotransmitter involved in its etiology and treatment. In this context, 5-HT1A receptors have attracted interest as…
read more here.
Keywords:
ht1a;
signaling mechanisms;
antidepressant effects;
molecular signaling ... See more keywords